Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases

被引:83
作者
de Pril, R
Fischer, DF
Maat-Schieman, MLC
Hobo, B
de Vos, RAI
Brunt, ER
Hol, EM
Roos, RAC
van Leeuwen, FW
机构
[1] Netherlands Inst Brain Res, Res Team Mol Misreading, NL-1105 AZ Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands
[3] Lab Pathol E Netherlands, NL-7512 AD Enschede, Netherlands
[4] Univ Groningen Hosp, Dept Neurol, NL-9713 AW Groningen, Netherlands
关键词
D O I
10.1093/hmg/ddh188
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Polyglutamine diseases are characterized by neuronal intranuclear inclusions (NIIs) of expanded polyglutamine proteins, indicating the failure of protein degradation. UBB+1, an aberrant form of ubiquitin, is a substrate and inhibitor of the proteasome, and was previously reported to accumulate in Alzheimer disease and other tauopathies. Here, we show accumulation of UBB+1 in the NIIs and the cytoplasm of neurons in Huntington disease and spinocerebellar ataxia type-3, indicating inhibition of the proteasome by polyglutamine proteins in human brain. We found that UBB+1 not only increased aggregate formation of expanded polyglutamines in neuronally differentiated cell lines, but also had a synergistic effect on apoptotic cell death due to expanded polyglutamine proteins. These findings implicate UBB+1 as an aggravating factor in polyglutamine-induced neurodegeneration, and clearly identify an important role for the ubiquitin-proteasome system in polyglutamine diseases.
引用
收藏
页码:1803 / 1813
页数:11
相关论文
共 47 条
[1]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[2]   Impairment of proteasome structure and function in aging [J].
Carrard, G ;
Bulteau, AL ;
Petropoulos, I ;
Friguet, B .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (11) :1461-1474
[3]   Evidence for proteasome involvement in polyglutamine disease:: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro [J].
Chai, YH ;
Koppenhafer, SL ;
Shoesmith, SJ ;
Perez, MK ;
Paulson, HL .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :673-682
[4]   Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila [J].
Chan, HYE ;
Warrick, JM ;
Andriola, I ;
Merry, D ;
Bonini, NM .
HUMAN MOLECULAR GENETICS, 2002, 11 (23) :2895-2904
[5]   The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg [J].
Ciechanover, A ;
Brundin, P .
NEURON, 2003, 40 (02) :427-446
[6]   Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice [J].
Cummings, CJ ;
Reinstein, E ;
Sun, YL ;
Antalffy, B ;
Jiang, YH ;
Ciechanover, A ;
Orr, HT ;
Beaudet, AL ;
Zoghbi, HY .
NEURON, 1999, 24 (04) :879-892
[7]   The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates [J].
de Cristofaro, T ;
Affaitati, A ;
Cariello, L ;
Avvedimento, EV ;
Varrone, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 260 (01) :150-158
[8]   Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death [J].
De Vrij, FMS ;
Sluijs, JA ;
Gregori, L ;
Fischer, DF ;
Hermens, WTJMC ;
Goldgaber, D ;
Verhaagen, J ;
Van Leeuwen, FW ;
Hol, EM .
FASEB JOURNAL, 2001, 15 (14) :2680-2688
[9]   Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain [J].
DiFiglia, M ;
Sapp, E ;
Chase, KO ;
Davies, SW ;
Bates, GP ;
Vonsattel, JP ;
Aronin, N .
SCIENCE, 1997, 277 (5334) :1990-1993
[10]   Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells [J].
Encinas, M ;
Iglesias, M ;
Liu, YH ;
Wang, HY ;
Muhaisen, A ;
Ceña, V ;
Gallego, C ;
Comella, JX .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (03) :991-1003